Muscarinic receptors in the bladder: From basic research to therapeutics

British Journal of Pharmacology

Volumn 147, Issue SUPPL. 2, 2006, Pages

  Hegde, Sharath S ^a  

^a THERAVANCE INC   (United States)

Author keywords

Antimuscarinic; Darifenacin; Micturition; Muscarinic; Overactive bladder; Oxybutynin; Solifenacin; Tolterodine; Trospium

Indexed keywords

CALCIUM CHANNEL L TYPE; CYCLIC AMP; DARIFENACIN; IPRATROPIUM BROMIDE; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXOTREMORINE; OXYBUTYNIN; RHO KINASE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

BLADDER CONTRACTION; BLADDER FUNCTION; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DETRUSOR MUSCLE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TOLERABILITY; ENZYME ACTIVATION; EXTRACELLULAR CALCIUM; HUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; PRURITUS; SMOOTH MUSCLE CONTRACTION; STATISTICAL SIGNIFICANCE; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; XEROSTOMIA;

ANIMALS; HUMANS; MICE; MICE, KNOCKOUT; MUSCARINIC ANTAGONISTS; PATIENT COMPLIANCE; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; RECEPTORS, MUSCARINIC; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 32544437047     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706560     Document Type: Conference Paper

References (63)

1. ABRAMS, P., CARDOZO, L., FALL, M., GRIFFITHS, D., ROSIER, P., ULMSTEN, U., VAN KERREBROECK, P., VICTOR, A. & WEIN, A. (2003). Standardisation Sub-Committee of the International Continence Society. Related Articles. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology, 61, 37-49.
2. ANDERSSON, K.E. (1999). Changes in bladder tone during filling: pharmacological aspects. Scand. J. Urol. Nephrol. Suppl., 201, 67-72.
3. ANDERSSON, K.E. & YOSHAIDA, M. (2003). Antimuscarinics and the overactive detrusor - which is the main mechanism of action? Eur. Urol., 43, 1-5.
4. ANDRADE, S.E., WALKER, A.M., GOTTLIEB, L.K., HOLLENBERG, N.K., TESTA, M.A., SAPERIA, G.M. & PLATT, R. (1995). Discontinuation of antihyperlipidemic drugs: Do rates reported in clinical trials reflect rates in primary care settings? New Engl. J. Meet., 332, 1125-1131.
5. CARDOZO, L., LISEC, M., MILLARD, R., VAN VIERSSEN TRIP, O., KUZMIN, I., DROGENDIJK, T.E., HUANG, M. & RIDDER, A.M. (2004). Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J. Urol., 172 (Part 1), 1919-1924.
6. CAULFIELD, M.P. & BIRDSALL, N.J. (1998). International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev., 50, 279-290.
7. 3 selective receptor antagonist, in the treatment of overactive bladder. B.J.U. Int., 95, 993-1001.
8. CHAPPLE, C.R., MARTINEZ-GARCIA, R., SELVAGGI, L., TOOZS-HOBSON, P., WARNACK, W., DROGENDIJK, T., WRIGHT, D.M., BOLODEOKU, J. & for the STAR study group (2005b). A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur. Urol., 48, 464-470.
9. CHAPPLE, C.R., YAMANISHI, T. & CHESS-WILLIAMS, R. (2002). Muscarinic receptor subtypes and management of the overactive bladder. Urology, 60 (Suppl 1), 82-88.
10. CHAPPLE, C., KHULLAR, V., GABRIEL, Z. & DOOLEY, J.A. (2005c). The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur. Urol., 48, 5-26.
11. CHESS-WILLIAMS, R. (2002). Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton. Autacoid Pharmacol., 22, 133-145.
12. 3-receptors mediates contraction of human detrusor muscle in vitro. J. Auton. Pharmacol., 21, 243-248.
13. CHUI, M.A., WILLIAMSON, T., ARCINIEGA, J., THOMPSON, C. & BENECKE, H. (2004). Patient persistency with medications for overactive bladder (abstract). Value Health, 7, 366.
14. 4 receptor subtype. Br. J. Pharmacol., 129, 493-500.
15. DE GROAT, W.C. (1997). A neurologic basis for the overactive bladder. Urology, 50 (Suppl), 36-52.
16. DE GROAT, W.C. (2004). The urothelium in overactive bladder: passive bystander or active participant? Urology, 64 (Suppl 1), 7-11.
17. DE GROAT, W.C., BOOTH, A.M. & YOSHIMURA, N. (1993). Neurophysiology of micturition and its modification in animal models of human disease. In: Nervous Control of the Urogenital System, ed. Maggi, C.A. pp. 227-290. New York: Harwood Acedemic Publishers.
18. DIOKNO, A., SAND, P., LABASKY, R., SIEBER, P., ANTOCI, J., LEACH, G., ATKINSON, L. & ALBRECHT, D. (2002). Long-term safety of extended release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int. Urol. Nephrol., 34, 43-49.
19. DIOKNO, A.C., APPELL, R.A., SAND, P.K, DMOCHOWSKI, R.R, GBUREK, B.M., KLIMBERG, I.W., KELL, S.H. & OPERA STUDY GROUP. (2003). Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin. Proc., 78, 687-695.
20. DMOCHOWSKI, R.R., SAND, P.K., ZINNER, N.R., GITTELMAN, M.C., DAVILA, G.W., SANDERS, S.W. & TRANSDERMAL OXYBUTYNIN STUDY GROUP. (2003). Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology, 62, 237-242.
21. DOROSHYENKO, O., JETTER, A., ODENTHAL, K.P. & FUHR, U. (2005). Clinical pharmacokinetics of trospium chloride. Clin. Pharmacokinet., 44, 701-720.
22. 2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. J. Pharmacol. Exp. Ther., 313, 368-378.
23. 3 muscarinic receptors mediate contraction of human urinary bladder. Br. J. Pharmacol., 136, 641-643.
24. FOVAEUS, M., FUJIWARA, M., HOGESTATT, E.D., PERSSON, K. & ANDERSSON, K.E. (1999). A non-nitrergic smooth muscle relaxant factor released from rat urinary bladder by muscarinic receptor stimulation. J. Urol., 161, 649-653.
25. GILLBERG, P.G., SUNDQUIST, S. & NILVEBRANT, L. (1998). Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur. J. Pharmacol., 349, 285-292.
26. GILLESPIE, J.I., HARVEY, L.J. & DRAKE, M.J. (2003). Agonist- and nerve-induced phasic activity in the whole isolated bladder of the guinea pig: evidence for two types of bladder activity. Exp. Physiol., 88, 343-357.
27. 3 antimuscarinic agent, in the anesthetised dog. Eur. Urol., 1 (Suppl. 1), 131.
28. HAAB, F. & CASTRO-DIAZ, D. (2005). Persistence with antimuscarinic therapy in patients with overactive bladder. Int. J. Clin. Pract., 59, 931-937.
29. HAAB, F., CARDOZO, L., CHAPPLE, C., RIDDER, A.M. & SOLIFENACIN STUDY GROUP. (2005). Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur. Urol., 47, 376-384.
30. HALASKA, M., RALPH, G., WIEDEMANN, A., PRIMUS, G., BALLERING-BRUHL, B., HOFNER, K & JONAS, U. (2003). Controlled, double-blind, multicenter clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J. Urol., 20, 392-399.
31. 3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J. Urol., 154, 1241-1245.
32. HAWTHORN, M.H., CHAPPLE, C.R., COCK, M. & CHESS-WILLIAMS, R. (2000). Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br. J. Pharmacol., 129, 416-419.
33. HEGDE, S.S. & EGLEN, R.M. (1999). Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci., 64, 419-428.
34. 3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br. J. Pharmacol., 120, 1409-1418.
35. HEGDE, S.S., MAMMEN, M. & JASPER, J.R. (2004). Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies. Curr. Opin. Investig. Drugs., 5, 40-49.
36. HERBISON, P., HAY-SMITH, J., ELLIS, G. & MOORE, K. (2003). Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ, 326, 841-844.
37. 3 receptors. J. Urol., 172 (Part 1 of 2), 2460-2464.
38. 3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn-Schmiedeberg's Arch. Pharmacol., 366, 97-103.
39. KERBUSCH, T., WAHLBY, U., MILLIGAN, P.A. & KARLSSON, M.O. (2003). Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br. J. Clin. Pharmacol., 56, 639-652.
40. KREDER, K., MAYNE, C. & JONAS, U. (2002). Long-term safety, tolerability and efficacy of extended release tolterodine in the treatment of overactive bladder. Eur. Urol., 41, 588-595.
41. 2 receptor knockout mice. J. Pharmacol. Exp. Ther., 305, 106-113.
42. 3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J. Neurosci., 22, 10627-10632.
43. NAKAMURA, T., MATSUI, M., UCHIDA, K., FUTATSUGI, A., KUSAKAWA, S., MATSUMOTO, N., NAKAMURA, K., MANABE, T., TAKETO, M.M. & MIKOSHIBA, K. (2004). M(3) muscarinic acetylcholine receptor plays a critical role in para sympathetic control of salivation in mice. J. Physiol., 558 (Part 2), 561-575.
44. NAPIER, C.M. & GUPTA, P. (2002). Darifenacin is selective for the human recombinant M3 receptor subtype. Neurourol. Vrodyn., 21, A445.
45. NILVEBRANT, L., ANDERSSON, K.E., GILLBERG, P.G., STAHL, M. & SPARF, B. (1997a). Tolterodine - a new bladder-selective antimuscarinic agent. Eur. J. Pharmacol., 327, 195-207.
46. NILVEBRANT, L., GILLBERG, P.G. & SPARF, B. (1997b). Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol. Toxicol., 81, 169-172.
47. NOE, L., SNEERINGER, R., PATEL, B. & WILLIAMSON, T. (2004). The implications of poor medication persistence with treatment for overactive bladder. Managed Care Interface, 17, 54-60.
48. OLSSON, B. & SZAMOSI, J. (2001). Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin. Pharmacokinet., 40, 227-235.
49. 2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am. J. Physiol. (Regul. Integr. Comp. Physiol.), 286, R874-R880.
50. SATHYAN, G., CHANCELLOR, M.B. & GUPTA, S.K. (2001). Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br. J. Clin. Pharmacol., 52, 409-417.
51. SCHNEIDER, T., FETSCHER, C., KREGE, S. & MICHEL, M.C. (2004). Signal transduction underlying carbachol-induced contraction of human urinary bladder. J. Pharmacol. Exp. Ther., 309, 1148-1153.
52. SMULDERS, R.A., KRAUWINKEL, W.J., SWART, P.J. & HUANG, M. (2004). Pharmacokinetics and safety of solifenacin succinate in healthy young men. J. Clin. Pharmacol., 44, 1023-1033.
53. 1 muscarinic receptor-mediated facilitation of acetylcholine release in the rat urinary bladder. J. Physiol., 480 (Part 1), 81-89.
54. STEVENS, L., CHAPPLE, C.R., TOPHILL, P. & CHESS-WILLIAMS, R. (2004a). A comparison of muscarinic receptor-mediated function in the normal and the neurogenic overactive bladder. J. Urol., 171, 143 (abstract 535).
55. STEVENS, L., CHESS-WILLIAMS, R. & CHAPPLE, C.R. (2004b). Muscarinic receptor function in the idiopathic overactive bladder. J. Urol., 171, 140-141.
56. 3H]acetylcholine in the rabbit urinary bladder. Eur. J. Pharmacol., 281, 1-8.
57. VAN KERREBROECK, P., KREDER, K., JONAS, U., ZINNER, N. & WEIN, A. (2001). Tolterodine Study Group: Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology, 57, 414-421.
58. WALDECK, K., LARSSON, B. & ANDERSSON, K.E. (1997). Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J. Urol., 157, 1093-1097.
59. WANG, P., LUTHIN, G.R. & RUGGIERI, M.R. (1995). Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J. Pharmacol. Exp. Ther., 273, 959-966.
60. WEIN, A.J. & ROVNER, E.S. (2002). Definition and epidemiology of overactive bladder. Urology, 60 (Suppl 1), 7-12.
61. 2-muscarinic receptors in mediating contraction of the pig urinary bladder in vitro. Br. J. Pharmacol., 131, 1482-1488.
62. 4 -receptor-deficient mice. Naunyn-Schmiedeberg's Arch. Pharmacol., 365, 112-122.
63. ZINNER, N., GITTELMAN, M., HARRIS, R., SUSSET, J., KANELOS, A., AUERBACH, S. & TROSPIUM STUDY GROUP. (2004). Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J. Urol., 171 (Part 1), 2311-2315.